Kenya Abridged Evaluation Route: Same Labeled Use and Field-by-Field Comparison

Content verified as of October 30, 2026

1. Key takeaways

• The core condition of the Abridged Evaluation Route is that the reference regulatory agency (RRA) approval must cover exactly the same labeled use as the intended market use.
• The count boundary is clear: Class B requires at least 2, Class C and Class D require at least 3.
• Same is not a category judgment but a field-by-field comparison: indication or testing target, intended population, use environment, user (professional or self-test), model or specification, and claims.
• A change of intended use is one of the five situations requiring submission of a new CSDT; changing from professional use to home use is a Review Change requiring prior approval.
• Under Section 5(2), PPB may approve or amend proprietary names, labels and promotional claims, so the power to adjust the boundary of use rests with PPB.
• Fee references: Class B registration USD 200, Class C/D USD 1,000 each; variation of a registered device USD 200.

2. Legal basis

3. Expert insights

Insight 1: The unit of comparison for the same labeled use is the field, not the product

The entire logic of a reliance route is that someone else has already reviewed this function of this product. The comparison must therefore descend to field level: whether the indication or testing target is the same, whether the intended population is the same (adults and children often differ), whether the use environment is the same (hospital, clinic, home), whether the user is the same (professionals versus lay users), whether the model falls within the approved scope, and whether the label claims are covered by the approved text. GRZAN’s practice is to build a comparison table of the intended label against each reference approval label, marking every field as same, narrower or broader. Only when every field lands in the first two columns is the abridged route safe.

Insight 2: Where subset and superset diverge

Two situations generate the most disputes in practice. The first is where the intended label is a subset of the reference approval label, for example the reference approval covers three indications and only one is filed. The reliance foundation exists here, because the reviewed content covers what is filed; GRZAN’s view is that the abridged route may be used, provided the trimmed scope is explained in the dossier. The second is where the intended label goes beyond the reference approval, adding an indication, a population or a home-use scenario. The excess has no reference review behind it and cannot be covered by the abridged route; the correct approach is to run full evaluation with supplementary data for the excess, or to file within the matching scope first and expand later through the variation procedure. Filing a superset as broadly similar is the most common ground for rejection on the abridged route.

Insight 3: Trimming the label to manufacture sameness stores up trouble for after launch

Some teams first trim the intended label until it matches the reference approval exactly, secure the certificate, then add the deleted uses back. The cost of this path is widely underestimated. First, a modification of the method of use that moves a product from professional to home use is expressly a Review Change requiring prior approval, not something a notification can implement. Second, a change of intended use is one of the five situations requiring a new CSDT, which returns the product to the starting line. Third, if a change notification is misclassified, the application is rejected and continued supply prohibited. Fourth, each variation carries the USD 200 variation fee. Trimming the label does not save work; it defers the cost and multiplies it.

Insight 4: The two-versus-three boundary reflects the demand for evidentiary redundancy

Class B requires at least 2 approvals and Class C/D at least 3, and this boundary extends the same logic as the expedited-route conditions: Class C/D ECR requires at least 3 approvals plus 5 years on the market, or at least 5 approvals. The higher the risk, the more independent review conclusions PPB demands. For Chinese companies, the common portfolio is an EU CE certificate plus a US FDA 510(k), enough for Class B but not for Class C/D. To enter the C/D abridged route, the third certificate usually has to come from TGA, Health Canada, MHLW, Swiss Medic, HPRA or SFDA, and the lead time for that certificate should be built into the project schedule from the start.

4. Practical recommendations

1. Build a label comparison table. Compare the intended label against every reference approval label field by field, marking same, narrower or broader.
2. Handle the broader parts separately. Content beyond the reference approvals goes through full evaluation with supplementary data and is not mixed into the abridged filing.
3. Freeze the intended label version. Keep the filing label and the final market label at the same version to avoid post-approval expansion.
4. Plan the third certificate early. Back-schedule the certificate acquisition plan for Class C/D products against the at least 3 requirement.
5. Classify variations correctly. Changes touching use, population or use scenario go through the prior-approval category, with the USD 200 variation fee budgeted.
6. Retain the comparison records. Archive the comparison table and the reasoning note together as the basis for answering review queries.

5. Verification checklist

• □ Has the field-by-field comparison between the intended label and each reference approval label been completed?
• □ Is there content beyond the reference approvals, and has it been handled separately under full evaluation?
• □ Does the number of reference approvals meet Class B 2 or Class C/D 3?
• □ Are the indication, population, use environment and user consistent across the reference approvals?
• □ Is the intended label version frozen, and is marketing aware that it may not expand it unilaterally?
• □ Are future variations correctly classified, and do any fall within the five situations requiring a new CSDT?
• □ Is the USD 200 variation fee in the budget?
• □ Is the lead time for the third reference approval for Class C/D built into the schedule?

Regulatory information verified as of October 30, 2026.

Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.

GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.

For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.